In partnership with:
Date:
30 September 2025, 16:00-17:00 CEST
Overview:
Unlock the future of cancer drug development with HUB Organoids. This webinar explores how patient-derived organoids (PDOs) are redefining oncology research. Discover how this advanced, well-characterized models empower researchers to streamline candidate selection, accelerate orphan drug programs, and deliver transformative therapies to patients faster than ever.
What you will learn:
- How HUB Organoids’ PDO biobanks enable rapid, data-driven prioritization of oncology drug candidates.
- The impact of organoid models on advancing orphan drug programs and targeting rare cancer indications.
- Real-world examples of accelerated drug discovery and development using HUB’s validated cancer organoids.
Speakers:
Dr. Robert Vries
CEO, HUB ORGANOIDS
Robert received his PhD in Biochemistry from the Leiden University Medical Center where he studied oncogenic cell transformation in the lab of Prof. van de Eb. He subsequently moved to Stanford University (USA) to pursue his post-doctoral career on neural stem cells.
Upon his return to the Netherlands, he joined the group of Prof. Hans Clevers at the Hubrecht Institute where he was involved in the development of the breakthrough “Organoid Technology” that allows the expansion of adult stem cells and the development of “mini-organs in a dish”.
Rob is currently CEO of HUB, which was founded to further develop and refine the Organoid Technology and was instrumental in the acquisition of HUB by the Life Science Business of Merck KGaA, Darmstadt, Germany.
Dylan Kissane
Host and Director of Editorial at Labiotech
Dylan Kissane is the Director of Editorial at Labiotech.
Born and raised in Western Australia, he earned undergraduate degrees in International Studies and Social Science at the University of South Australia before moving to Europe to complete his postgraduate studies. His doctoral research focused on the nexus of complexity theory, chaos theory, and international relations theory, and he earned his Ph.D. in 2010.
After several years working as a professor and tertiary education administrator, he left academia to join a small technology startup where he led their content creation team. Later, he worked for a deep tech scale-up company, where he was promoted rapidly from thought leadership manager to Vice President of Marketing. In 2019, he left to launch his own consultancy and has been working independently since then.
Beginning in 2023, he started covering selected biopharma partnering conferences and events for Labiotech. In March 2025, he began hosting the Beyond Biotech podcast, and in July 2025, he was appointed Director of Editorial.